Scholarlink

Background <p>Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy resulting from the dysregulation of the alternative complement pathway. Pathogenic variants in complement regulators (e.g., <i>CFH</i>, <i>CFI</i>, <i>CD46</i>, <i>THBD</i>), effectors (<i>C3</i>, <i>CFB</i>), <i>CFHR</i> genes, and non-complement genes (e.g., <i>DGKE</i>, <i>INF2</i>), as well as anti-factor H autoantibodies, play significant roles in disease pathogenesis. Furthermore, numerous <i>CFH-CFHR</i> hybrid genes are increasingly recognized as significant contributors to aHUS pathogenesis. Among these, epidemiological data on <i>CD46</i>-associated aHUS remain limited. Here, we present a case of aHUS associated with a rare novel homozygous mutation in the <i>CD46</i> gene (c.1127 + 2T &gt; A).</p> Case presentation <p>We present a case of a 27-year-old Chinese male diagnosed with atypical Hemolytic Uremic Syndrome (aHUS) at the age of 8, who has experienced seven relapses over a span of 19 years. Whole-exome sequencing (WES) revealed a novel homozygous mutation in the <i>CD46</i> gene (c.1127 + 2T &gt; A; intron 12 splice site), which is classified as pathogenic according to ACMG guidelines and has not been previously reported. Sanger sequencing confirmed the presence of this variant. Further analyses demonstrated significantly reduced CD46 mRNA and protein expression in the patient’s peripheral blood compared to healthy controls and his mother, as assessed by qPCR and ELISA.</p> Conclusion <p>In our study, a novel mutation in the <i>CD46</i> gene (c.1127 + 2T &gt; A) was identified via WES and confirmed to affect the transcription and translation of CD46, thereby contributing to the pathogenesis of aHUS. This finding broadens the spectrum of <i>CD46</i> gene variants associated with aHUS, providing a critical basis for clinical diagnosis, genetic counseling, and treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of a new CD46 gene mutation site in a family with atypical hemolytic uremic syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月22日

查看全文
  • Benjin Hu,
  • Xu Wang,
  • Xian Wang,
  • Hongchuan Zhang,
  • Dongdong Mei,
  • Xiaohua Guo,
  • Xiaowei Li

摘要

Background

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy resulting from the dysregulation of the alternative complement pathway. Pathogenic variants in complement regulators (e.g., CFH, CFI, CD46, THBD), effectors (C3, CFB), CFHR genes, and non-complement genes (e.g., DGKE, INF2), as well as anti-factor H autoantibodies, play significant roles in disease pathogenesis. Furthermore, numerous CFH-CFHR hybrid genes are increasingly recognized as significant contributors to aHUS pathogenesis. Among these, epidemiological data on CD46-associated aHUS remain limited. Here, we present a case of aHUS associated with a rare novel homozygous mutation in the CD46 gene (c.1127 + 2T > A).

Case presentation

We present a case of a 27-year-old Chinese male diagnosed with atypical Hemolytic Uremic Syndrome (aHUS) at the age of 8, who has experienced seven relapses over a span of 19 years. Whole-exome sequencing (WES) revealed a novel homozygous mutation in the CD46 gene (c.1127 + 2T > A; intron 12 splice site), which is classified as pathogenic according to ACMG guidelines and has not been previously reported. Sanger sequencing confirmed the presence of this variant. Further analyses demonstrated significantly reduced CD46 mRNA and protein expression in the patient’s peripheral blood compared to healthy controls and his mother, as assessed by qPCR and ELISA.

Conclusion

In our study, a novel mutation in the CD46 gene (c.1127 + 2T > A) was identified via WES and confirmed to affect the transcription and translation of CD46, thereby contributing to the pathogenesis of aHUS. This finding broadens the spectrum of CD46 gene variants associated with aHUS, providing a critical basis for clinical diagnosis, genetic counseling, and treatment.